Advertisement
Advertisement
U.S. markets close in 2 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Appili Therapeutics Inc. (APLIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.05930.0000 (0.00%)
As of 03:27PM EDT. Market open.
Advertisement

Appili Therapeutics Inc.

#21-1344 Summer Street
Halifax, NS B3H 0A8
Canada

https://www.appilitherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Dr. Armand Balboni J.D., M.D., Ph.D.CEO & Director284.11kN/A1966
Dr. Yoav Golan M.S., M.D., MSChief Medical Officer252.47kN/A1962
Dr. Donald D. Cilla Jr., M.B.A., Pharm.D., PharmdChief Devel. Officer317.53kN/AN/A
Mr. Kenneth G. HowlingActing Chief Financial OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Corporate Governance

Appili Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement